Management and outcome of metastatic melanoma during pregnancy
C. Pagès(Inserm), M. Viguier(Inserm), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Sixtine de Raucourt, B. Sassolas(Centre Hospitalier Régional Universitaire de Brest), S. Dalac(CHU Dijon Bourgogne), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), Amir Khammari(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), D Fichet(Centre Hospitalier Universitaire Henri-Mondor), L. Thomas(University of Liverpool), P Stoebner(Centre Hospitalier Universitaire de Nîmes), Caroline Robert(Institut Gustave Roussy), Christine Chevreau(Institut Claudius Regaud), F. Boitier(Délégation Paris 5), E. Maubec(Inserm), P. Celérier(Centre Hospitalier de La Rochelle)
Cited by 71
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k